N\u00e4r L\u00e4kemedelsverket summerar f\u00f6rra \u00e5rets biverkningsrapportering framg\u00e5r det tydligt att viktminskningsl\u00e4kemedlen semaglutid (Ozempic, Rybeslus, Wegovy) och tirzepatid (Mounjaro) sticker ut. De b\u00e5da substanserna toppar listan p\u00e5 enskilda substanser d\u00e4r biverkningar rapporterats 2025.<\/p>\n
\u2013 Det \u00e4r dock viktigt att po\u00e4ngtera att de flesta av dessa rapporter klassas som icke allvarliga och r\u00f6r biverkningar som redan \u00e4r k\u00e4nda sedan tidigare. Vi ser samtidigt att f\u00f6rskrivningen har \u00f6kat, s\u00e4ger Emilia\u00a0Lekholm, enhetschef f\u00f6r l\u00e4kemedelss\u00e4kerhet p\u00e5 L\u00e4kemedelsverket\u00a0i ett pressmeddelande.<\/p>\n
Totalt inkom 12\u00a0615 biverkningsrapporter till L\u00e4kemedelsverket\u00a0f\u00f6rra \u00e5ret\u00a0d\u00e4r n\u00e4rmare 60 procent kom fr\u00e5n h\u00e4lso- och sjukv\u00e5rden och resten skickades in av privatpersoner.<\/p>\n
Rapportering \u2013 en god g\u00e4rning<\/p>\n
Varje enskild rapport \u00e4r en viktig pusselbit f\u00f6r att \u00f6ka kunskapen om ett l\u00e4kemedels s\u00e4kerhetsprofil, skriver L\u00e4kemedelsverket. Vissa biverkningar, s\u00e4rskilt de s\u00e4llsynta, uppt\u00e4cks f\u00f6rst n\u00e4r ett l\u00e4kemedel har anv\u00e4nts av en stor population under en l\u00e4ngre tid. D\u00e4rf\u00f6r uppmanar L\u00e4kemedelsverket b\u00e5de v\u00e5rdpersonal och allm\u00e4nhet att forts\u00e4tta rapportera.<\/p>\n","protected":false},"excerpt":{"rendered":"N\u00e4r L\u00e4kemedelsverket summerar f\u00f6rra \u00e5rets biverkningsrapportering framg\u00e5r det tydligt att viktminskningsl\u00e4kemedlen semaglutid (Ozempic, Rybeslus, Wegovy) och tirzepatid (Mounjaro)…\n","protected":false},"author":2,"featured_media":230702,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[18059,72,70,71,34,2653,31,33,32,30,15201],"class_list":["post-230701","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-biverkningar","tag-business","tag-economy","tag-ekonomi","tag-se","tag-semaglutid","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-tirzepatid"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116481550083424626","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/230701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=230701"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/230701\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/230702"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=230701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=230701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=230701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}